Harvard Pilgrim Health Care | TUFTS Health Plan

Pharmacy Medical Necessity Guidelines: **Northera (droxidopa)**

Effective: August 12, 2025

Guideline Type	☒ Prior Authorization ☐ Non-Formulary ☐ Step-Therapy ☐ Administrative

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products; Fax: 617-673-0988

☒ Tufts Health Plan Commercial products; Fax: 617-673-0988

CareLink℠ – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization

Public Plans Products

☒ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax: 617-673-0988

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

Overview

Food and Drug Administration – Approved Indications

Northera (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Effectiveness of Northera (droxidopa) beyond two weeks of treatment has not been demonstrated. The continued effectiveness of Northera (droxidopa) should be assessed periodically.

Clinical Guideline Coverage Criteria

The plan may authorize coverage of droxidopa (generic Northera) for patients when **ALL** of the following criteria are met:

1. Documented diagnosis of symptomatic neurogenic orthostatic hypotension

AND

2. Patient has had a trial and failure, inadequate response, intolerance, or contraindication to both midodrine and fludrocortisone.

Limitations

- For a non-formulary medication request, please refer to the Pharmacy Medical Necessity Guidelines for Formulary Exceptions and submit a formulary exception request to the plan as indicated.

Codes

None

References

1. Food and Drug Administration. Midodrine update. 2010 September 10. URL: fda.gov/drugs/drugsafety/ucm225444.htm. Available from Internet. Accessed 2014 June 28.
2. Food and Drug Administration. Drugs@FDA.URL: accessdata.fda.gov/Scripts/cder/drugsatfda. Available from Internet. Accessed 2014a June 23.
3. Food and Drugs Administration. Northera (droxidopa) Advisory Committee Briefing Document. January 14, 2014b. URL: fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenal DrugsAdvisoryCommittee/UCM381155.pdf. Available from Internet. Accessed 2014 July 7.
4. Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008; 358(6):615-24.
5. Freeman R, Wieling W, Axelrod FB et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69–72.
6. Isaacson S, Hauser RA, Szakacs CB et al. Droxidopa treatment on orthostatic symptoms and standing systolic blood pressure in patients with Parkinson's disease and symptomatic neurogenic orthostatic hypotension: study 306. Poster

presented at the 65th annual meeting of the American Academy of Neurology. San Diego, CA; 2013 March 16-23. Poster 010.
7. Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169-76.
8. Kaufmann H, Malamut R, Norcliffe-Kaufmann L et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012; 22(2):79-90.
9. Kaufmann H, Freeman R, Biaggioni et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. In press.
10. Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician. 2011; 84(5):527-536.
11. Low PA. Prevalance of orthostatic hypotension. Clin Auton Res. 2008; 18(Suppl 1):8-13.
12. Metzler M, Duerr S, Granata R et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013; 260(9):2212-9.
13. Prescribing information. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2017 February.
14. National Institute for Health and Care Excellence (NICE). URL: nice.org.uk/. Available from Internet. Accessed 2014 July 3.
15. Northera prescribing information. Deerfield, IL: Lundbeck NA Ltd.; 2020 April.
16. Parsaik AK, Singh B, Altayar O et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013; 28(11):1496-503.
17. Pharmaceutical Benefit Scheme. URL: pbs.gov.au/pbs/home. Available from Internet. Accessed 2014 July 3.
18. Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich). 2013;15(3):147-53.

Approval And Revision History

September 2022: Reviewed by the Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

- August 8, 2023: No changes
- August 13, 2024: No changes
- August 12, 2025: No changes

Background, Product and Disclaimer Information

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.